Boston Partners Akebia Therapeutics, Inc. Transaction History

Boston Partners

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 12, 2020	SELL	$6.67 - $13.58 $466,920 - $950,640	-70,003 Closed	0 $0
Q1 2020 May 13, 2020	SELL	$4.1 - $10.24 $696,241 - $1.74 Million	-169,815 Reduced 70.81%	70,003 $531,000
Q4 2019 Feb 05, 2020	SELL	$3.16 - $6.73 $195,240 - $415,813	-61,785 Reduced 20.49%	239,818 $1.52 Million
Q3 2019 Nov 20, 2019	BUY	$3.55 - $5.4 $196,446 - $298,819	55,337 Added 22.47%	301,603 $1.18 Million
Q2 2019 Aug 09, 2019	SELL	$4.1 - $8.05 $150,789 - $296,062	-36,778 Reduced 12.99%	246,266 $1.19 Million
Q1 2019 May 03, 2019	BUY	$5.41 - $8.73 $19,833 - $32,004	3,666 Added 1.31%	283,044 $2.32 Million
Q4 2018 Feb 07, 2019	BUY	$5.39 - $9.15 $1.51 Million - $2.56 Million	279,378 New	279,378 $1.55 Million

120

54.8M

291K

179K

Ticker AKBA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 183,848,992
Market Cap $324M
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...

Get notified when there are updates to the investment portfolio of Boston Partners, based on Form 13F filings with the SEC.

Stay updated on Boston Partners with notifications on news.